{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004561","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.084112+00:00","generated_at":"2026-05-31T10:39:52.145993+00:00","sec_items":["2.02","3.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cassava Sciences reports Q2 net income, $40M SEC loss contingency, Phase 3 readout timeline","bullets":["Q2 net income $6.2M vs net loss $26.4M in 2023, driven by non-cash warrant gain.","Recorded $40M loss contingency for advanced discussions to resolve SEC investigation.","Cash $207.3M at June 30, 2024; no debt; warrants fully exercised.","Phase 3 RETHINK-ALZ top-line data expected by end of 2024; REFOCUS-ALZ mid-2025.","Audit Committee vacancy due to director death; Nasdaq noncompliance; cure until Aug 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004561","json":"https://secwatch.observer/filing/0001171843-24-004561.json","markdown":"https://secwatch.observer/filing/0001171843-24-004561.md","text":"https://secwatch.observer/filing/0001171843-24-004561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/0001171843-24-004561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324004561/f8k_080824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:39:52.145993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}